Advanced Analytics. Intelligent Insights.

We are a premier neuroimaging provider, working with pharma and biotech partners to improve the outcomes of clinical trials.

logo-outline

Phase II Alzheimer’s disease contract award worth >£1m

IXICO plc, the AI data analytics company delivering insights in neuroscience, announces that it has been awarded an expansion contract by a current biopharmaceutical client to support the company’s Phase II Alzheimer’s disease clinical trial.

READ MORE

AD/PD 2021 Poster - Automatic segmentation using deep learning for the hippocampus

READ MORE

Going for growth: IXICO primed to solve the challenge of increased clinical trial complexity through AI advances

Article written by ShareBuyers Editorial Team originally published here As part of the ShareBuyers’ going for growth series, we take a look into the growth prospects of IXICO (IXI), the AIM-listed specialist in AI data analysis for the international clinical trial market which has seen its share price increase by 80% over the past six months....

READ MORE

AAIC 2021 - Alzheimer's Association International Conference

Join in-person or virtually for AAIC 2021, where the world’s leading basic scientists, clinical researchers, early career investigators, clinicians and the care research community will share breaking research discoveries that will lead to methods of prevention and treatment and improvements in diagnosis for Alzheimer’s disease.

READ MORE

Senior Test Engineer

READ MORE

Advanced Analytics. Intelligent Insights.

We are a premier neuroimaging provider, working with pharma and biotech partners to improve the outcomes of clinical trials.

At IXICO, we are advancing medicine by transforming data into clinically meaningful insights. We bring together world-class therapeutic expertise in central nervous system diseases, breakthrough technology and analytics, and operational excellence. This makes us the partner of choice for imaging biomarker solutions in CNS clinical trials.

Your medical imaging partner

We support biopharmaceutical companies across all phases of their CNS clinical research.

Consultancy

We can work with you on the selection and use of medical imaging and digital biomarkers for your drug development programs, directly and as part of collaborative consortia.

Read more

Early Phase

We are experts in the definition and delivery of early phase clinical development, where rigorous patient safety runs hand-in-hand with flexibility around trial design and data analytics.



Read more

Late Phase

Our global network of over 2,000 imaging centers across 75 countries ensures large-scale trials can be set up quickly and efficiently, while our custom TrialTracker platform delivers highly reliable, regulatory compliant data.

Read more

Post-Marketing

We understand the challenges of extended longitudinal studies. We support you to monitor patient safety and drug utilization for ongoing optimization of patient pathways post-marketing.

Read more

Speacialist Therapeutic Focus

We have focused exclusively on neurological disorders since 2004, and our growing team are renowned experts in CNS therapeutics. We combine specialist neuroscience knowledge, highly curated neurological patient data and proven pipeline algorithms to accurately measure brain biomarkers. This enables us to confidently and accurately answer research questions related to disease symptoms, delivery mechanism, mode of action, drug safety and efficacy.

The diseases we work on include:

Alzheimer's Disease (AD)

IXICO is a leading provider at the forefront of advancing Alzheimer's disease (AD) imaging biomarkers, having focused on AD clinical research since 2007. We have conducted over 40 Alzheimer's disease studies, bringing together deep therapeutic expertise, breakthrough AI analytics and operational agility to deliver extraordinary clinical insights.

Read more

Huntington's Disease (HD)

IXICO is the leading company for Huntington's disease (HD) specialist imaging. Our neuroscience expertise enables global, regulatory compliant imaging and digital biomarker analytical services for clinical development. We are a trusted imaging provider and preferred supplier for pharma and biotech, with IXICO providing advanced imaging analytics for 11 HD trials.

Read more

Parkinson's Disease (PD)

IXICO first supported a clinical study for PD in 2016 and continue to invest in our technological solutions to support clinical trials in this area. PD is the second most common neurodegenerative disease, after Alzheimer’s disease. An estimated 7 to 10 million people worldwide are living with PD.

Read more

Multiple Sclerosis (MS)

We have been involved in MS since 2015 through our Assessa PML collaboration with big pharma. Multiple Sclerosis is a condition that affects the brain and spinal cord. It is the most common autoimmune disorder of the central nervous system, affecting around 2.3 million people globally as of 2015.

Read more

Progressive Supranuclear Palsy

Progressive Supranuclear Palsy (PSP) is a Parkinsonian neurological rare condition caused by the premature loss of nerve cells in certain parts of the brain, which leads to difficulties with balance, movement, vision, speech and swallowing. IXICO has supported clinical trials in this area since 2015, providing advanced analytics for 5 clinical trials across 230 global sites.

Read more

Other Rare Neurological Diseases

IXICO specialises in data collection, optimisation, and analytics of rare neurological disorders, including but not limited to Huntington's Disease (HD), Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), and Spinocerebellar Ataxia (SCA).

Read more
Scanner icon 2

Imaging Biomarkers

Scanner icon 2

Imaging Biomarkers

We are at the forefront of developing and validating unique neuroimaging methods and MRI and PET image analysis techniques. This enables us to provide you with accurate, rich structural and functional information.

Digital Brain icon 2

Digital Biomarkers

Digital Brain icon 2

Digital Biomarkers

We are continuously developing and validating new machine learning algorithms to analyse wearable biosensor data for neurodegenerative diseases. Disease-specific algorithms improve the sensitivity and specificity of standard algorithms when measuring physiological parameters including sleep, activity and circadian rhythm.

AI icon 2

Analytics & AI

AI icon 2

Analytics & AI

In neuroscience, AI has applications across the entire spectrum of understanding and treating disease. Our sophisticated AI technology and analytics support your clinical development programmes by interpreting complex patient data into valuable insight.

Data platforms icon 2

Data Platforms

Data platforms icon 2

Data Platforms

Our fully compliant image and digital data management provides everything you need to manage complex data workflows in CNS clinical trials. Our secure online digital platform supports your clinical decision-making, from patient selection to post-marketing surveillance.